Wedbush set a $35.00 price objective on Lexicon Pharmaceuticals (NASDAQ:LXRX) in a research note released on Tuesday morning, TipRanks reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
A number of other research firms also recently issued reports on LXRX. BidaskClub raised Lexicon Pharmaceuticals from a sell rating to a hold rating in a research report on Thursday, March 14th. Gabelli cut Lexicon Pharmaceuticals from a hold rating to a sell rating in a research note on Wednesday, March 13th. ValuEngine upgraded Lexicon Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, March 12th. Needham & Company LLC restated a hold rating on shares of Lexicon Pharmaceuticals in a research note on Monday, March 25th. Finally, Stifel Nicolaus decreased their price objective on Lexicon Pharmaceuticals from $14.00 to $10.00 and set a buy rating for the company in a research note on Monday, March 25th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus target price of $16.38.
LXRX opened at $5.53 on Tuesday. Lexicon Pharmaceuticals has a 12-month low of $4.25 and a 12-month high of $13.97. The firm has a market cap of $587.67 million, a PE ratio of -4.85 and a beta of 0.77.
A number of institutional investors have recently bought and sold shares of the stock. BNP Paribas Arbitrage SA raised its holdings in Lexicon Pharmaceuticals by 940.2% during the 1st quarter. BNP Paribas Arbitrage SA now owns 9,934 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 8,979 shares during the period. Wealth & Pension Services Group Inc. purchased a new stake in Lexicon Pharmaceuticals during the 1st quarter valued at $60,000. Pegasus Asset Management Inc. purchased a new stake in Lexicon Pharmaceuticals during the 4th quarter valued at $66,000. M&T Bank Corp purchased a new stake in Lexicon Pharmaceuticals during the 1st quarter valued at $66,000. Finally, Federated Investors Inc. PA raised its holdings in Lexicon Pharmaceuticals by 1,317.0% during the 1st quarter. Federated Investors Inc. PA now owns 12,611 shares of the biopharmaceutical company’s stock valued at $70,000 after buying an additional 11,721 shares during the period. 98.30% of the stock is currently owned by hedge funds and other institutional investors.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Recommended Story: Stock Symbols Definition, Examples, Lookup
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.